SNUBH Clinical Pharmacololgy and Therapeutics

Medicine & Life Sciences

1. Pharmacokinetics 100%
2. Healthy Volunteers 53%
3. Metformin 27%
4. Genotype 21%
5. Therapeutic Equivalency 20%
6. Pharmaceutical Preparations 17%
7. Area Under Curve 15%
8. Safety 14%
9. Tablets 12%
10. Placebos 12%
11. Genetic Polymorphisms 11%
12. Oral Administration 10%
13. Atorvastatin 10%
14. Vancomycin 10%
15. delpazolid 9%
16. Alleles 9%
17. Cytochrome P-450 CYP2B6 9%
18. Cross-Over Studies 9%
19. Cytochrome P-450 CYP3A 8%
20. Single Nucleotide Polymorphism 8%
21. olmesartan 8%
22. Moxifloxacin 8%
23. Population 8%
24. Elderly 7%
25. Proton Pump Inhibitors 7%
26. Ursodeoxycholic Acid 6%
27. Rabbits 6%
28. pitavastatin 6%
29. Citalopram 6%
30. Haplotypes 6%
31. Oxazolidinones 6%
32. Volunteers 6%
33. Pregnane X Receptor 6%
34. Half-Life 6%
35. aflibercept 6%
36. Lorazepam 6%
37. Urine 6%
38. Cytochrome P-450 CYP2C19 6%
39. 2-hydroxyatorvastatin 5%
40. Amlodipine 5%
41. 3-(3-ethyl-5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-5-methylbenzonitrile 5%
42. Biological Availability 5%
43. Cilostazol 5%
44. Glucose 5%
45. Eye 5%
46. Clinical Studies 5%
47. Losartan 5%
48. Young Adult 5%
49. Ranibizumab 5%
50. Rifampin 5%
51. Valproic Acid 5%